CD4+ cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis
LI Chirwa, JA Johnson, RW Niska, TM Segolodi…�- Aids, 2014 - journals.lww.com
We examined CD4+ cell count and plasma viral load patterns among Botswana TDF/FTC
Oral HIV Prophylaxis Trial (TDF2 study) participants who seroconverted, comparing�…
Oral HIV Prophylaxis Trial (TDF2 study) participants who seroconverted, comparing�…
High rates of drug resistance in individuals diagnosed with HIV in tenofovir disoproxil fumarate (TDF)-based pre-exposure prophylaxis rollout programs in Kenya�…
Background: The ongoing rollout of oral TDF-based PrEP has the potential to reduce HIV
incidence in Sub-Saharan Africa (SSA) but HIV drug resistance (HIVDR) in PrEP�…
incidence in Sub-Saharan Africa (SSA) but HIV drug resistance (HIVDR) in PrEP�…
Brief Report: HIV-1 evolution in breakthrough infections in a human trial of oral pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil fumarate
S Ruone, L Paxton, T McLaurin, A Taylor…�- JAIDS Journal of�…, 2016 - journals.lww.com
We describe HIV-1 evolutionary dynamics in the 4 participants from the TDF2-PrEP trial who
became HIV-1 infected while prescribed emtricitabine and tenofovir disoproxil fumarate�…
became HIV-1 infected while prescribed emtricitabine and tenofovir disoproxil fumarate�…
HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial
NJ Garrett, L Werner, N Naicker…�- JAIDS Journal of�…, 2015 - journals.lww.com
Background: Although antiretroviral pre-exposure prophylaxis prevents HIV acquisition, it is
not known if it alters HIV disease progression. This study assesses whether tenofovir gel�…
not known if it alters HIV disease progression. This study assesses whether tenofovir gel�…
[HTML][HTML] The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion
Objective: To investigate whether oral preexposure prophylaxis (PrEP) alters timing and
patterns of seroconversion when PrEP use continues after HIV-1 infection. Design�…
patterns of seroconversion when PrEP use continues after HIV-1 infection. Design�…
Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed�…
N Prada, B Davis, P Jean-Pierre…�- JAIDS Journal of�…, 2008 - journals.lww.com
Background: Continued high rates of HIV-1 transmission have fueled interest in the use of
antiretrovirals to prevent infection. Attenuated infection with failure of tenofovir as�…
antiretrovirals to prevent infection. Attenuated infection with failure of tenofovir as�…
Characterization of HIV seroconverters in a TDF/FTC PrEP study: HPTN 067/ADAPT
MV Sivay, M Li, E Piwowar-Manning…�- JAIDS Journal of�…, 2017 - journals.lww.com
Background: HIV Prevention Trials Network (HPTN) 067/ADAPT evaluated tenofovir
disoproxil fumarate/emtricitabine (TDF/FTC) pre-exposure prophylaxis (PrEP) in women�…
disoproxil fumarate/emtricitabine (TDF/FTC) pre-exposure prophylaxis (PrEP) in women�…
Race/ethnicity and protease inhibitor use influence plasma tenofovir exposure in adults living with HIV-1 in AIDS clinical trials group study A5202
CJ Bednasz, CS Venuto, Q Ma, ES Daar…�- Antimicrobial agents�…, 2019 - Am Soc Microbiol
ABSTRACT AIDS Clinical Trial Group study A5202 (ClinicalTrials. gov identifier
NCT00118898) was a phase 3b, randomized, partially blinded equivalence study of open�…
NCT00118898) was a phase 3b, randomized, partially blinded equivalence study of open�…
Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single-or dual-agent preexposure prophylaxis
Abstract Background. Preexposure prophylaxis (PrEP) with emtricitabine plus tenofovir
disoproxil fumarate (FTC/TDF) or TDF alone reduces the risk of human immunodeficiency�…
disoproxil fumarate (FTC/TDF) or TDF alone reduces the risk of human immunodeficiency�…
[HTML][HTML] HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention
Background: Antiretroviral pre-exposure prophylaxis (PrEP) is a novel HIV prevention
strategy for which adherence is a known determinant of efficacy. Blood concentrations of�…
strategy for which adherence is a known determinant of efficacy. Blood concentrations of�…
Related searches
- viral load cell count
- viral load hiv infections
- hiv infections cell count
- viral load drug resistance
- drug resistance cell count
- hiv infections drug resistance
- drug resistance preexposure prophylaxis
- drug resistance dual agent
- drug resistance high rates
- hiv transmission preexposure prophylaxis
- dual agent preexposure prophylaxis
- emtricitabine and tenofovir breakthrough infections
- disoproxil fumarate breakthrough infections